In this conversation, Jonathan López, a medical doctor and founder of karē Corp, discusses his innovative approach to biotech, focusing on a modular platform for drug delivery in extreme environments. He shares his journey from med school to entrepreneurship, the challenges he faced, and his vision for making a global impact, particularly for Puerto Rico. The discussion highlights the importance of real-time health monitoring and the potential applications of his technology in defense and emergency response.Chapters:00:00 Introduction to Next-Gen Biotech05:05 The Vision Behind karē Corp10:00 The Modular Platform Explained15:11 Real-Time Monitoring and Team Awareness19:58 Challenges and Growth as a Founder24:56 The Shift from Cannabis to Defense29:59 Current Status and Future AspirationsGuest Information:Guest's Name: Jonathan LópezGuest's Title/Position:  Founder & CEOGuest's Linkedin: https://www.linkedin.com/in/jonathanlopez92/Company / Affiliation: karē Corp  https://karembio.com/Guest's Bio: Jonathan López is the Founder and CEO of karē Corp, a physician-trained entrepreneur focused on building regulated, science-first human performance systems. His work centers on the development of advanced subcutaneous infusion platforms that integrate pharmacology, hardware, and software to support human health and performance in demanding environments.Jonathan leads the company’s strategy across FDA-regulated development pathways, intellectual property creation, and dual-use deployment for civilian healthcare, first responders, defense, and space applications. He is currently advancing multiple patented platforms designed to align with federal innovation and research programs, with the goal of delivering next-generation biomedical solutions for extreme and mission-critical environments. Takeaways:Jonathan López is building next-gen biotech platforms for drug delivery.karē Corp aims to provide real-time health monitoring in extreme environments.The platform is modular and can be tailored for different users like soldiers and astronauts.Real-time data can help prevent medical emergencies in the field.Jonathan's journey reflects the challenges of pursuing innovation in healthcare.He emphasizes the importance of inspiring Puerto Ricans to believe in their potential.The shift from cannabis to defense technology was a strategic decision for broader impact.Jonathan faced external doubt from family and friends about his entrepreneurial path.The technology aims to enhance human performance in critical situations.Jonathan is currently in the process of securing grants and patents for his innovations.The Healthy Enterprise Podcast is produced by Bullzeye Global Growth Partners  https://bullzeyeglobal.com/

This episode is part of a limited series called Money Ball in conjunction with the BLPN Club . BLPN's Money Ball program helps founders step up to the plate and knock fundraising out of the park. You'll hear about the people, their ventures, and their pitch-making experiences.In this episode of The Healthy Enterprise, host Heath Fletcher speaks with Chandi Bandara, CEO of Precision Quantomics, about the challenges and innovations in drug development. They discuss the inefficiencies in the pharmaceutical industry, the importance of effective pitching to investors, and the insights gained from the Money Ball program. Chandi shares his journey from a molecular biologist to a CEO, the lessons learned in storytelling for pitches, and the significance of feedback in refining business strategies. The conversation emphasizes the need for entrepreneurs to seek guidance and input from experienced peers in their journey.Chapters:00:00 Introduction to The Healthy Enterprise and Money Ball Series00:39 Chandi Bandara: CEO of Precision Quantomics02:04 Innovative Solutions in Drug Development03:49 Company Progress and Market Presence05:07 Chandi's Journey to Precision Quantomics06:26 The Art of Pitching to Investors09:00 Crafting the Perfect Pitch Story11:28 Refining the Pitch with Money Ball Program13:30 Learning from Investor Feedback15:22 Common Mistakes in Pitching18:17 Unique Perspective as a Non-Founder CEO20:03 Impact of Money Ball Program on Pitching22:28 Advice for Aspiring Entrepreneurs25:54 Conclusion and Future AspirationsGuest Information:Guest's Name: Chandi BandaraGuest's Title/Position:  Chief Executive OfficerGuest's Linkedin: https://www.linkedin.com/in/cabandara/Company / Affiliation: Precision Quantomics https://precisionquantomics.com/Guest's Bio:  Chandima Bandara is CEO of Precision Quantomics, where he leads the company’s mission to transform drug development through high-precision proteomics. With more than 20 years of experience across biotechnology, contract research, business development, and large-scale operations, he brings a unique blend of scientific expertise and operational leadership to the biotech industry.He began his career in R&D before scaling growth at a leading CRO and later managing world-class logistics operations at Amazon. Over the past six years, he has focused on commercializing scientific innovation through life sciences startups. At Precision Quantomics, he is building a comprehensive proteomics database, LC-MS kit portfolio, and testing-as-a-service platform to accelerate pharmaceutical R&D and reduce costs. Chandima also serves on the Board of Trustees for the Health Sciences & Services Authority of Spokane County and contributes to national initiatives advancing regulatory science and New Approach Methodologies.Takeaways:Precision Quantomics addresses inefficiencies in drug development.90% of drugs fail to reach the market due to outdated models.Chandi Bandara transitioned from science to business development.Effective pitching requires understanding the audience's perspective.The Money Ball program helped refine Chandi's pitch.Investors need to hear the problem and solution quickly.Iterating on the pitch deck is crucial for success.Feedback from investors is invaluable for improvement.Every entrepreneur's journey is unique and requires tailored advice.Building a supportive ecosystem is essential for startup growth.

This episode is part of a limited series called Money Ball in conjunction with the BLPN Club. BLPN's Money Ball program helps founders step up to the plate and knock fundraising out of the park. You'll hear about the people, their ventures, and their pitch-making experiences.In this episode of The Healthy Enterprise, host Heath Fletcher interviews Doug Cohen, the Co-Founder and CEO of IR Medtek, about his journey in developing a groundbreaking technology for cancer detection. Doug shares his unique background in mechanical engineering and how it led him to identify a significant gap in the healthcare market, particularly in skin cancer detection. The conversation delves into the development process of their innovative device, the challenges faced, and the importance of refining their pitch to investors through the Money Ball program. Doug emphasizes the value of collaboration, confidence in their technology, and the potential impact on patient care.Chapters:00:00 Introduction to Money Ball and IR Medtek01:14 Doug's Unique Background and Journey02:27 Identifying the Gap in Cancer Detection05:51 The Development Journey of the Technology07:41 Current Progress and Future Steps08:39 Understanding the Device and Its Functionality10:58 Enhancing Primary Care with Technology13:25 Investor Response and Presentation Experience14:34 Refining the Pitch through Money Ball18:32 Public Speaking and CEO Responsibilities21:12 The Advantage of an Engineering Background24:11 Reflections on the Money Ball ExperienceGuest Information:Guest's Name: Doug CohenGuest's Title/Position: Chief Executive OfficerGuest's Linkedin: https://www.linkedin.com/in/doug-cohen-64761410/Company / Affiliation: IR Medtek https://www.irmedtek.com/Guest's Bio:  Doug Cohen is IR Medtek's Co-Founder and CEO and has over 20 years of experience in manufacturing equipment, product design, global sourcing, and logistics. Doug is a graduate of MIT in mechanical engineering and has experience as both an owner and investor in start-ups. He owns a number of technology patents and serves on the board of the public company Organovo.Takeaways:Doug's background in mechanical engineering shaped his approach to IR Medtek.The technology developed can differentiate tumor from non-tumor tissue.Skin cancer detection is a significant market opportunity.The device provides real-time feedback to primary care doctors.Investor confidence is crucial for the success of startups.Refining the pitch can significantly improve investor engagement.Public speaking skills are essential for CEOs in fundraising.Collaboration with experts enhances the team's capabilities.The Money Ball program provided valuable networking opportunities.The technology has the potential to improve patient outcomes significantly.The Healthy Enterprise Podcast is produced by Bullzeye Global Growth Partners  https://bullzeyeglobal.com/

This episode is part of a limited series called Money Ball in conjunction with the BLPN Club . BLPN's Money Ball program helps founders step up to the plate and knock fundraising out of the park. You'll hear about the people, their ventures, and their pitch-making experiences.In this episode, Rob Boyce, CEO of Plakous Therapeutics, discusses the company's mission to develop regenerative medicine solutions for necrotizing enterocolitis (NEC), a devastating disease affecting premature infants. He shares insights into the challenges of developing treatments for this vulnerable population, the importance of funding, and the role of networking in the biotech industry. Rob also highlights a case study of a patient named Laurel, illustrating the potential impact of their product on improving outcomes for babies at risk of NEC.Chapters:00:00 Introduction to Plakous Therapeutics01:08 Understanding Necrotizing Enterocolitis (NEC)04:23 The Genesis of Plakous Therapeutics06:24 Innovative Approach to Treatment09:27 Real-Life Impact: Case Study of Laurel13:32 Navigating the Funding Landscape16:06 Refining the Pitch Process22:05 Challenges in the Current Investment Climate25:11 Current Stage and Future PlansGuest Information:Guest's Name: Robert BoyceGuest's Title/Position:  Chief Executive OfficerGuest's Linkedin:https://www.linkedin.com/in/robertwboyce/Company / Affiliation: Plakous Therapeutics https://www.plakoustherapeutics.com/Guest's Bio:  Rob Boyce is the CEO of Plakous Therapeutics, Rob has been working in healthcare and life sciences throughout his career. He has been part of several start-up companies. Prior to Plakous Rob was at Imago Systems, Inc., a software as a service medical diagnostic company seeking to redefine the medical imaging. He started his business career at Johnson & Johnson, marketing the Tylenol Brand. While at J&J he led worldwide Sales and Marketing for Independence Technology, a Johnson & Johnson company specializing in state-of-the-art rehabilitation technology. Rob launched his career as a naval flight officer in the Navy’s E-2C Hawkeye.Takeaways:Rob Boyce is the CEO of Plakous Therapeutics, focusing on regenerative medicine.Necrotizing enterocolitis (NEC) is a severe condition affecting premature infants.The last FDA-approved medicine for NICU babies was in 1991.Plakous's product mimics amniotic fluid to support GI tract development.Laurel's case illustrates the challenges faced by NEC patients.Funding for pediatric biotech is particularly challenging.Networking and preparation are crucial for successful investor pitches.Understanding the audience is key to effective presentations.Regulatory pathways for pediatric treatments are complex and uncertain.Plakous aims to raise $8 million for further development.The Healthy Enterprise Podcast is produced by Bullzeye Global Growth Partners https://bullzeyeglobal.com/

This episode is part of a limited series called Money Ball in conjunction with the BLPN Club . BLPN's Money Ball program helps founders step up to the plate and knock fundraising out of the park. You'll hear about the people, their ventures, and their pitch-making experiences.In this conversation, James Lovgren shares his insights on the funding process for biotech startups, emphasizing the importance of team expertise, the art of pitching, and the need to balance scientific detail with storytelling. He discusses the iterative nature of pitching, the significance of understanding investor expectations, and the value of targeting the right investors to enhance the chances of success. James reflects on his experiences in the Money Ball program, highlighting the lessons learned and the importance of adaptability in investor conversations.Chapters:00:00 Introduction to Money Ball and Aspiro Therapeutics01:13 Understanding Obstructive Lung Diseases02:59 Innovative Solutions in Lung Disease Treatment05:04 The Journey of Aspiro Therapeutics07:05 The Importance of Team Dynamics09:09 Mastering the Pitch Process10:50 Evolving the Pitch: Lessons Learned12:58 Investor Engagement and Feedback14:56 Navigating Investor Relationships17:09 Refining the Pitch Through Iteration19:01 The Role of Investor Fit21:07 Future Directions for Aspiro TherapeuticsGuest Information:Guest's Name: James LovgrenGuest's Title/Position:  CEO & Co-FounderGuest's Linkedin: https://www.linkedin.com/in/jameslovgren/Company / Affiliation: Aspiro Therapeutics https://aspirotx.com/Guest's Bio:  As the CEO of Aspiro Therapeutics, James Lovgren leads the company’s mission to revolutionize the treatment of obstructive lung diseases with innovative CC16-inspired therapies.James is an accomplished life science executive with a distinguished track record of commercializing disruptive technologies and managing global product portfolios exceeding $250 million. His extensive background spans startups, growth-stage companies, and Fortune 150 biotechnology firms, where he has successfully brought a wide range of products, services, and reagents to market in the pharmaceutical, diagnostics, and life science sectors.James’ strategic insight and operational expertise are instrumental in guiding Aspiro Therapeutics through its preclinical development stage and beyond.Takeaways:Investors prioritize team expertise in funding decisions.The pitching process requires practice and iteration.Balancing scientific detail with storytelling is crucial.Understanding investor backgrounds can shape the pitch.Feedback from peers can refine the pitch effectively.High-level narratives often resonate more than technical data.Each investor may have different areas of interest.Flexibility in presentation can lead to better engagement.Building a targeted investor list saves time and effort.Long-term relationships with investors are essential for success.The Healthy Enterprise Podcast is produced by Bullzeye Global Growth Partners  https://bullzeyeglobal.com/